Study on the mechanism and pharmacokinetics of HB-NC4 based on C5b-9 target in the treatment of osteoarthritis.

Osteoarthritis (OA) is a chronic degenerative disease that mostly occurs in elderly individuals over 60 years old. The detailed pathogenesis of OA is unclear. Medicines available on the market are nonsteroidal anti-inflammatory drugs. Therefore, in this study, a fusion protein was introduced, and the detailed mechanism that could alleviate OA was discussed. As a targeted protein, HB-NC4 showed better binding ability to chondrocytes, and its half-life period was prolonged compared to NC4 alone. In addition, HB-NC4 can not only affect the levels of C3 and C5, but also inhibit the formation of the membrane-attack complex (MAC, C5b-9), thereby further affecting the expression of MAPK signalling pathway-related proteins to achieve the goal of treating OA. Thus, in this study, we demonstrate the pharmacokinetics of HB-NC4 and its mechanism to alleviate OA by regulating the complement system and MAPK signalling pathway. This study provides a new method for OA therapy based on fusion proteins.

Study Progress in Pharmacokinetics of Proton Pump Inhibitors / 中国药师

Proton pump inhibitors are H+ /K+-ATPase inhibitors, which can efficiently inhibit gastric acid secretion for a long time. As the latest inhibitory gastric acid drugs, proton pump inhibitors are the best choices for acid-related diseases such as gastroe-sophageal reflux disease, peptic ulcer and gastrointestinal lesions caused by nonsteroidal anti-inflammatory drugs. Proton pump inhibi-tors have significant inhibition to basal gastric acid, night gastric acid and gastric acid secretion caused by gastrin and food stimulation. This article reviewed the pharmacokinetic characteristics of five proton pump inhibitors in domestic market.